Heidelberg Pharma AG (FRA:HPHA)
2.810
0.00 (0.00%)
At close: Nov 28, 2025
Heidelberg Pharma AG Revenue
Heidelberg Pharma AG had revenue of 47.13K EUR in the quarter ending August 31, 2025, a decrease of -96.05%. This brings the company's revenue in the last twelve months to 3.04M, down -64.15% year-over-year. In the fiscal year ending November 30, 2024, Heidelberg Pharma AG had annual revenue of 6.85M, down -30.53%.
Revenue (ttm)
3.04M
Revenue Growth
-64.15%
P/S Ratio
44.36
Revenue / Employee
26.64K
Employees
105
Market Cap
134.73M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Nov 30, 2024 | 6.85M | -3.01M | -30.53% |
| Nov 30, 2023 | 9.86M | -8.66M | -46.75% |
| Nov 30, 2022 | 18.51M | 16.48M | 810.30% |
| Nov 30, 2021 | 2.03M | -6.63M | -76.53% |
| Nov 30, 2020 | 8.67M | 1.17M | 15.63% |
| Nov 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 136.97B |
| Bayerische Motoren Werke Aktiengesellschaft | 136.42B |
| Deutsche Telekom AG | 121.02B |
| Allianz SE | 105.02B |
| Siemens Aktiengesellschaft | 78.91B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Siemens Energy AG | 39.08B |
| SAP SE | 36.49B |
Heidelberg Pharma AG News
- 26 days ago - EQS-News: Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma - Wallstreet:Online
- 4 weeks ago - EQS-News: Heidelberg Pharma to Present New Clinical Data of Lead ADC Candidate HDP-101 at the World ADC Congress 2025 and to Host Webinar - Wallstreet:Online
- 7 weeks ago - EQS-NVR: Heidelberg Pharma AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution - Wallstreet:Online
- 7 weeks ago - Heidelberg Pharma's Bold Moves in 2025's First 9 Months - Wallstreet:Online
- 7 weeks ago - EQS-News: Heidelberg Pharma Reports on the First Nine Months of Financial Year 2025 - Wallstreet:Online
- 2 months ago - Heidelberg Pharma AG Boosts Outlook: Exciting New Guidance Revealed! - Wallstreet:Online
- 2 months ago - EQS-Adhoc: Heidelberg Pharma AG Announces Updated Guidance - Wallstreet:Online
- 2 months ago - EQS-News: Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma - Wallstreet:Online